Logo image of EXAS

EXACT SCIENCES CORP (EXAS) Stock Fundamental Analysis

NASDAQ:EXAS - Nasdaq - US30063P1057 - Common Stock - Currency: USD

51.55  +4.39 (+9.31%)

After market: 51.65 +0.1 (+0.19%)

Fundamental Rating

4

Overall EXAS gets a fundamental rating of 4 out of 10. We evaluated EXAS against 567 industry peers in the Biotechnology industry. EXAS has a bad profitability rating. Also its financial health evaluation is rather negative. EXAS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year EXAS has reported negative net income.
EXAS had a positive operating cash flow in the past year.
In the past 5 years EXAS always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
EXAS Yearly Net Income VS EBIT VS OCF VS FCFEXAS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M -800M -1B

1.2 Ratios

EXAS has a better Return On Assets (-17.36%) than 80.60% of its industry peers.
EXAS has a Return On Equity of -42.83%. This is in the better half of the industry: EXAS outperforms 68.96% of its industry peers.
Industry RankSector Rank
ROA -17.36%
ROE -42.83%
ROIC N/A
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
EXAS Yearly ROA, ROE, ROICEXAS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

EXAS has a Gross Margin of 69.55%. This is amongst the best in the industry. EXAS outperforms 81.13% of its industry peers.
EXAS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EXAS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
EXAS Yearly Profit, Operating, Gross MarginsEXAS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

3

2. Health

2.1 Basic Checks

EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EXAS has been increased compared to 1 year ago.
The number of shares outstanding for EXAS has been increased compared to 5 years ago.
EXAS has a worse debt/assets ratio than last year.
EXAS Yearly Shares OutstandingEXAS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
EXAS Yearly Total Debt VS Total AssetsEXAS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

Based on the Altman-Z score of 1.13, we must say that EXAS is in the distress zone and has some risk of bankruptcy.
EXAS's Altman-Z score of 1.13 is fine compared to the rest of the industry. EXAS outperforms 68.08% of its industry peers.
The Debt to FCF ratio of EXAS is 87.70, which is on the high side as it means it would take EXAS, 87.70 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 87.70, EXAS belongs to the top of the industry, outperforming 92.42% of the companies in the same industry.
A Debt/Equity ratio of 0.97 indicates that EXAS is somewhat dependend on debt financing.
EXAS has a Debt to Equity ratio of 0.97. This is in the lower half of the industry: EXAS underperforms 77.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 87.7
Altman-Z 1.13
ROIC/WACCN/A
WACC9.1%
EXAS Yearly LT Debt VS Equity VS FCFEXAS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

EXAS has a Current Ratio of 2.15. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
EXAS has a Current ratio of 2.15. This is in the lower half of the industry: EXAS underperforms 73.72% of its industry peers.
EXAS has a Quick Ratio of 1.92. This is a normal value and indicates that EXAS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.92, EXAS is doing worse than 74.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.92
EXAS Yearly Current Assets VS Current LiabilitesEXAS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for EXAS have decreased strongly by -292.42% in the last year.
The Revenue has grown by 10.37% in the past year. This is quite good.
Measured over the past years, EXAS shows a very strong growth in Revenue. The Revenue has been growing by 25.78% on average per year.
EPS 1Y (TTM)-292.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65%
Revenue 1Y (TTM)10.37%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%10.86%

3.2 Future

Based on estimates for the next years, EXAS will show a very strong growth in Earnings Per Share. The EPS will grow by 20.14% on average per year.
Based on estimates for the next years, EXAS will show a quite strong growth in Revenue. The Revenue will grow by 10.49% on average per year.
EPS Next Y91.39%
EPS Next 2Y44.6%
EPS Next 3Y30.7%
EPS Next 5Y20.14%
Revenue Next Year11.21%
Revenue Next 2Y12.1%
Revenue Next 3Y11.74%
Revenue Next 5Y10.49%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EXAS Yearly Revenue VS EstimatesEXAS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
EXAS Yearly EPS VS EstimatesEXAS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 101.64, EXAS can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 90.30% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.86. EXAS is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 101.64
EXAS Price Earnings VS Forward Price EarningsEXAS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EXAS is valued cheaply inside the industry as 91.53% of the companies are valued more expensively.
EXAS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXAS is cheaper than 92.59% of the companies in the same industry.
Industry RankSector Rank
P/FCF 329.03
EV/EBITDA 304.3
EXAS Per share dataEXAS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

EXAS's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as EXAS's earnings are expected to grow with 30.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.6%
EPS Next 3Y30.7%

More info and screens

0

5. Dividend

5.1 Amount

EXAS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXACT SCIENCES CORP

NASDAQ:EXAS (5/2/2025, 8:00:02 PM)

After market: 51.65 +0.1 (+0.19%)

51.55

+4.39 (+9.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners100.85%
Inst Owner Change-0.03%
Ins Owners0.99%
Ins Owner Change4.46%
Market Cap9.72B
Analysts85.29
Price Target68.72 (33.31%)
Short Float %5.86%
Short Ratio4.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-695.49%
Min EPS beat(2)-1391.93%
Max EPS beat(2)0.95%
EPS beat(4)2
Avg EPS beat(4)-336.22%
Min EPS beat(4)-1391.93%
Max EPS beat(4)72.6%
EPS beat(8)6
Avg EPS beat(8)-142.98%
EPS beat(12)10
Avg EPS beat(12)-89.43%
EPS beat(16)11
Avg EPS beat(16)-65.9%
Revenue beat(2)0
Avg Revenue beat(2)-1.73%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)-0.27%
Revenue beat(4)0
Avg Revenue beat(4)-1.12%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)-0.27%
Revenue beat(8)2
Avg Revenue beat(8)0.62%
Revenue beat(12)6
Avg Revenue beat(12)1.31%
Revenue beat(16)10
Avg Revenue beat(16)1.62%
PT rev (1m)-3.66%
PT rev (3m)-7.34%
EPS NQ rev (1m)0.83%
EPS NQ rev (3m)-7.81%
EPS NY rev (1m)-14.63%
EPS NY rev (3m)2.59%
Revenue NQ rev (1m)-0.11%
Revenue NQ rev (3m)-1.25%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 101.64
P/S 3.52
P/FCF 329.03
P/OCF 46.18
P/B 4.05
P/tB N/A
EV/EBITDA 304.3
EPS(TTM)-5.18
EYN/A
EPS(NY)0.51
Fwd EY0.98%
FCF(TTM)0.16
FCFY0.3%
OCF(TTM)1.12
OCFY2.17%
SpS14.63
BVpS12.74
TBVpS-5.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.36%
ROE -42.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.55%
FCFM 1.07%
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 87.7
Debt/EBITDA 65.54
Cap/Depr 84.24%
Cap/Sales 6.56%
Interest Coverage N/A
Cash Conversion 591.13%
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.92
Altman-Z 1.13
F-Score3
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-292.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65%
EPS Next Y91.39%
EPS Next 2Y44.6%
EPS Next 3Y30.7%
EPS Next 5Y20.14%
Revenue 1Y (TTM)10.37%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%10.86%
Revenue Next Year11.21%
Revenue Next 2Y12.1%
Revenue Next 3Y11.74%
Revenue Next 5Y10.49%
EBIT growth 1Y16.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year307.3%
EBIT Next 3Y79.87%
EBIT Next 5Y51.21%
FCF growth 1Y-5.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.86%
OCF growth 3YN/A
OCF growth 5YN/A